MYL3

Across TCGA pan-cancer cohorts, MYL3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of MYL3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MYL3 RNA is repressed in tumor relative to normal tissue. In most cancer types MYL3 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and LUAD are the cancer types where MYL3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYL3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−1.656	<.001	12	view →
KICH	Female	III,IV	−4.820	<.001	11	view →
LUAD	Female	III,IV	−1.342	<.001	11	view →
BLCA	Male	All	−1.293	<.001	11	view →
HNSC	Male	All	−2.855	<.001	8	view →
STAD	All	All	−0.642	<.001	8	view →
LUSC	Female	All	−1.320	<.001	7	view →
UCEC	All	II,III,IV	−1.504	<.001	6	view →
BRCA	All	II,III,IV	−0.783	<.001	6	view →
KIRP	All	III,IV	−1.662	.008	3	view →
CHOL	All	II,III,IV	−1.055	.046	2	view →
PRAD	All	All	−1.027	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

MYL3–KIRC

Open the KIRC breakdown →